Bacopaside I
Internal ID | 763b14b1-8498-4b5d-b74a-cdcc5c52d580 |
Taxonomy | Lipids and lipid-like molecules > Prenol lipids > Triterpenoids |
IUPAC Name | [(2R,3S,4S,5R,6S)-6-[(2S,3R,4S,5S)-3-[(2S,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-5-hydroxy-2-[[(1S,2R,5R,7S,10R,11R,14R,15S,16S,17R,20R)-16-hydroxy-2,6,6,10,16-pentamethyl-17-(2-methylprop-1-enyl)-19,21-dioxahexacyclo[18.2.1.01,14.02,11.05,10.015,20]tricosan-7-yl]oxy]oxan-4-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl hydrogen sulfate |
SMILES (Canonical) | CC(=CC1COC23CC4(CO2)C(C3C1(C)O)CCC5C4(CCC6C5(CCC(C6(C)C)OC7C(C(C(CO7)O)OC8C(C(C(C(O8)COS(=O)(=O)O)O)O)O)OC9C(C(C(O9)CO)O)O)C)C)C |
SMILES (Isomeric) | CC(=C[C@@H]1CO[C@]23C[C@]4(CO2)[C@@H]([C@H]3[C@@]1(C)O)CC[C@H]5[C@]4(CC[C@@H]6[C@@]5(CC[C@@H](C6(C)C)O[C@H]7[C@@H]([C@H]([C@H](CO7)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)COS(=O)(=O)O)O)O)O)O[C@H]9[C@@H]([C@H]([C@@H](O9)CO)O)O)C)C)C |
InChI | InChI=1S/C46H74O20S/c1-21(2)14-22-16-59-46-19-45(20-60-46)23(37(46)44(22,7)54)8-9-28-42(5)12-11-29(41(3,4)27(42)10-13-43(28,45)6)64-40-36(66-38-33(52)30(49)25(15-47)62-38)35(24(48)17-58-40)65-39-34(53)32(51)31(50)26(63-39)18-61-67(55,56)57/h14,22-40,47-54H,8-13,15-20H2,1-7H3,(H,55,56,57)/t22-,23-,24+,25+,26-,27+,28-,29+,30+,31-,32+,33-,34-,35+,36-,37+,38+,39+,40+,42+,43-,44+,45+,46-/m1/s1 |
InChI Key | SKFWOYHZBNAJGA-YAOMZRCFSA-N |
Popularity | 28 references in papers |
Molecular Formula | C46H74O20S |
Molecular Weight | 979.10 g/mol |
Exact Mass | 978.44941592 g/mol |
Topological Polar Surface Area (TPSA) | 308.00 Ų |
XlogP | 1.10 |
Atomic LogP (AlogP) | 0.29 |
H-Bond Acceptor | 19 |
H-Bond Donor | 9 |
Rotatable Bonds | 11 |
382148-47-2 |
Bacopaside I, (-)- |
BACOPASIDE I(SH) |
UNII-36B8WUA361 |
36B8WUA361 |
Bacopaside I (constituent of bacopa) [DSC] |
[(2R,3S,4S,5R,6S)-6-[(2S,3R,4S,5S)-3-[(2S,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-5-hydroxy-2-[[(1S,2R,5R,7S,10R,11R,14R,15S,16S,17R,20R)-16-hydroxy-2,6,6,10,16-pentamethyl-17-(2-methylprop-1-enyl)-19,21-dioxahexacyclo[18.2.1.01,14.02,11.05,10.015,20]tricosan-7-yl]oxy]oxan-4-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl hydrogen sulfate |
3-O-alpha-L-arabinofuranosyl-(1-2)-(6-O-sulphonyl-beta-D-glucopyranosyl-(1-3))-alpha-L-arabinopyranosyl pseudo-jujubogenin |
HY-N4246 |
AKOS040760286 |
There are more than 10 synonyms. If you wish to see them all click here. |

Target | Value | Probability (raw) | Probability (%) |
---|---|---|---|
Human Intestinal Absorption | + | 0.8007 | 80.07% |
Caco-2 | - | 0.8806 | 88.06% |
Blood Brain Barrier | + | 0.6000 | 60.00% |
Human oral bioavailability | - | 0.7000 | 70.00% |
Subcellular localzation | Mitochondria | 0.4949 | 49.49% |
OATP2B1 inhibitior | - | 0.8774 | 87.74% |
OATP1B1 inhibitior | + | 0.8227 | 82.27% |
OATP1B3 inhibitior | + | 0.9306 | 93.06% |
MATE1 inhibitior | - | 0.9800 | 98.00% |
OCT2 inhibitior | - | 0.7250 | 72.50% |
BSEP inhibitior | + | 0.7528 | 75.28% |
P-glycoprotein inhibitior | + | 0.7543 | 75.43% |
P-glycoprotein substrate | + | 0.5853 | 58.53% |
CYP3A4 substrate | + | 0.7524 | 75.24% |
CYP2C9 substrate | - | 0.8002 | 80.02% |
CYP2D6 substrate | - | 0.8537 | 85.37% |
CYP3A4 inhibition | - | 0.8370 | 83.70% |
CYP2C9 inhibition | - | 0.7521 | 75.21% |
CYP2C19 inhibition | - | 0.7185 | 71.85% |
CYP2D6 inhibition | - | 0.8706 | 87.06% |
CYP1A2 inhibition | - | 0.7463 | 74.63% |
CYP2C8 inhibition | + | 0.7147 | 71.47% |
CYP inhibitory promiscuity | - | 0.8771 | 87.71% |
UGT catelyzed | + | 0.6000 | 60.00% |
Carcinogenicity (binary) | - | 0.5800 | 58.00% |
Carcinogenicity (trinary) | Non-required | 0.5478 | 54.78% |
Eye corrosion | - | 0.9794 | 97.94% |
Eye irritation | - | 0.9035 | 90.35% |
Skin irritation | - | 0.7477 | 74.77% |
Skin corrosion | - | 0.9064 | 90.64% |
Ames mutagenesis | - | 0.6054 | 60.54% |
Human Ether-a-go-go-Related Gene inhibition | + | 0.7322 | 73.22% |
Micronuclear | + | 0.5600 | 56.00% |
Hepatotoxicity | - | 0.8500 | 85.00% |
skin sensitisation | - | 0.8407 | 84.07% |
Respiratory toxicity | + | 0.6667 | 66.67% |
Reproductive toxicity | + | 0.8778 | 87.78% |
Mitochondrial toxicity | - | 0.5125 | 51.25% |
Nephrotoxicity | - | 0.8163 | 81.63% |
Acute Oral Toxicity (c) | III | 0.5760 | 57.60% |
Estrogen receptor binding | + | 0.8017 | 80.17% |
Androgen receptor binding | + | 0.7567 | 75.67% |
Thyroid receptor binding | - | 0.5116 | 51.16% |
Glucocorticoid receptor binding | + | 0.7404 | 74.04% |
Aromatase binding | + | 0.6230 | 62.30% |
PPAR gamma | + | 0.7983 | 79.83% |
Honey bee toxicity | - | 0.5663 | 56.63% |
Biodegradation | - | 0.7250 | 72.50% |
Crustacea aquatic toxicity | - | 0.5055 | 50.55% |
Fish aquatic toxicity | + | 0.9854 | 98.54% |
Proven Targets:
CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
---|---|---|---|---|---|
No proven targets yet! |
Predicted Targets (via Super-PRED):
CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
---|---|---|---|---|
CHEMBL325 | Q13547 | Histone deacetylase 1 | 96.93% | 95.92% |
CHEMBL226 | P30542 | Adenosine A1 receptor | 96.63% | 95.93% |
CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 96.02% | 96.09% |
CHEMBL2581 | P07339 | Cathepsin D | 94.32% | 98.95% |
CHEMBL4685 | P14902 | Indoleamine 2,3-dioxygenase | 92.31% | 96.38% |
CHEMBL4187 | Q99250 | Sodium channel protein type II alpha subunit | 91.84% | 95.50% |
CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 91.83% | 91.11% |
CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 91.62% | 97.25% |
CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 91.48% | 95.56% |
CHEMBL1937 | Q92769 | Histone deacetylase 2 | 90.88% | 94.75% |
CHEMBL1994 | P08235 | Mineralocorticoid receptor | 90.78% | 100.00% |
CHEMBL3145 | P42338 | PI3-kinase p110-beta subunit | 89.69% | 98.75% |
CHEMBL3137262 | O60341 | LSD1/CoREST complex | 89.37% | 97.09% |
CHEMBL4478 | Q00975 | Voltage-gated N-type calcium channel alpha-1B subunit | 89.36% | 97.14% |
CHEMBL241 | Q14432 | Phosphodiesterase 3A | 89.21% | 92.94% |
CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 89.00% | 94.45% |
CHEMBL3524 | P56524 | Histone deacetylase 4 | 88.47% | 92.97% |
CHEMBL5255 | O00206 | Toll-like receptor 4 | 88.34% | 92.50% |
CHEMBL2111367 | P27986 | PI3-kinase p110-alpha/p85-alpha | 87.26% | 94.33% |
CHEMBL5888 | Q99558 | Mitogen-activated protein kinase kinase kinase 14 | 87.24% | 100.00% |
CHEMBL1907602 | P06493 | Cyclin-dependent kinase 1/cyclin B1 | 86.02% | 91.24% |
CHEMBL3476 | O15111 | Inhibitor of nuclear factor kappa B kinase alpha subunit | 85.74% | 95.83% |
CHEMBL1806 | P11388 | DNA topoisomerase II alpha | 85.38% | 89.00% |
CHEMBL3922 | P50579 | Methionine aminopeptidase 2 | 84.96% | 97.28% |
CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 83.60% | 96.90% |
CHEMBL218 | P21554 | Cannabinoid CB1 receptor | 83.57% | 96.61% |
CHEMBL5469 | Q14289 | Protein tyrosine kinase 2 beta | 83.31% | 91.03% |
CHEMBL2274 | Q9H228 | Sphingosine 1-phosphate receptor Edg-8 | 82.61% | 100.00% |
CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 82.52% | 95.89% |
CHEMBL1075094 | Q16236 | Nuclear factor erythroid 2-related factor 2 | 82.39% | 96.00% |
CHEMBL1871 | P10275 | Androgen Receptor | 81.89% | 96.43% |
CHEMBL2095194 | P08709 | Coagulation factor VII/tissue factor | 81.89% | 99.17% |
CHEMBL1907603 | Q05586 | Glutamate NMDA receptor; GRIN1/GRIN2B | 81.79% | 95.89% |
CHEMBL340 | P08684 | Cytochrome P450 3A4 | 81.50% | 91.19% |
CHEMBL4026 | P40763 | Signal transducer and activator of transcription 3 | 81.49% | 82.69% |
CHEMBL4145 | Q9UKV0 | Histone deacetylase 9 | 80.92% | 85.49% |
CHEMBL4303 | P08238 | Heat shock protein HSP 90-beta | 80.50% | 96.77% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
PubChem | 21599442 |
NPASS | NPC295232 |
LOTUS | LTS0087888 |
wikiData | Q27256548 |